Literature DB >> 19414790

Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes.

Hualin Li1, Chong-Feng Xu, Steven Blais, Qi Wan, Hui-Tang Zhang, Samuel J Landry, Catarina E Hioe.   

Abstract

Glycosylation of HIV-1 envelope gp120 determines not only the proper structure, but also the immune responses against this Ag. Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448. These glycans are required for efficient MHC class II-restricted presentation of nearby CD4 T cell epitopes, even though they are not part of the epitopes. The glycans do not affect CD4 T cell recognition of more distant epitopes and are not essential for the proper folding and function of gp120. Data on CD4 T cell recognition of N448 mutants combined with proteolysis analyses and surface electrostatic potential calculation around residue N448 support the notion that N448 glycan near the epitope's C terminus renders the site to be surface accessible and allows its efficient processing. In contrast, the N230 glycan contributes to the nearby epitope presentation at a step other than the proteolytic processing of the epitope. Hence, N-glycans can determine CD4 T cell recognition of nearby gp120 epitopes by regulating the different steps in the MHC class II processing and presentation pathway after APCs acquire the intact gp120 Ag exogenously. Modifications of amino acids bearing glycans at the C termini of gp120 helper epitopes may prove to be a useful strategy for enhancing the immunogenicity of HIV-1 envelope gp120.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414790      PMCID: PMC2808118          DOI: 10.4049/jimmunol.0804287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

3.  Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

Authors:  C E Hioe; G J Jones; A D Rees; S Ratto-Kim; D Birx; C Münz; M K Gorny; M Tuen; S Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  2000-06-10       Impact factor: 2.205

4.  Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope.

Authors:  Surojit Sarkar; Vandana Kalia; Michael Murphey-Corb; Ronald C Montelaro
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

5.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

8.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.

Authors:  P B Fischer; G B Karlsson; T D Butters; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects.

Authors:  Sandra Cohen; Michael Tuen; Catarina E Hioe
Journal:  AIDS Res Hum Retroviruses       Date:  2003-09       Impact factor: 2.205

Review 10.  Proteolysis and antigen presentation by MHC class II molecules.

Authors:  Paula Wolf Bryant; Ana-Maria Lennon-Duménil; Edda Fiebiger; Cécile Lagaudrière-Gesbert; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2002       Impact factor: 3.543

View more
  26 in total

1.  HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome.

Authors:  Srinika Ranasinghe; Michael Flanders; Sam Cutler; Damien Z Soghoian; Musie Ghebremichael; Isaiah Davis; Madelene Lindqvist; Florencia Pereyra; Bruce D Walker; David Heckerman; Hendrik Streeck
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 2.  Post-translationally modified T cell epitopes: immune recognition and immunotherapy.

Authors:  Jan Petersen; Anthony W Purcell; Jamie Rossjohn
Journal:  J Mol Med (Berl)       Date:  2009-09-08       Impact factor: 4.599

3.  Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4.

Authors:  Christian St-Pierre; Hiroshi Manya; Michel Ouellet; Gary F Clark; Tamao Endo; Michel J Tremblay; Sachiko Sato
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

4.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

5.  Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Authors:  Christine Hager-Braun; Elisabeth O Hochleitner; Miroslaw K Gorny; Susan Zolla-Pazner; Rachelle J Bienstock; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-31       Impact factor: 3.109

Review 6.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

7.  Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Authors:  Rajnish Kumar; Michael Tuen; Jianping Liu; Arthur Nàdas; Ruimin Pan; Xiangpeng Kong; Catarina E Hioe
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

Review 8.  Why Glycosylation Matters in Building a Better Flu Vaccine.

Authors:  Deborah Chang; Joseph Zaia
Journal:  Mol Cell Proteomics       Date:  2019-10-11       Impact factor: 5.911

9.  Adaptive immune activation: glycosylation does matter.

Authors:  Margreet A Wolfert; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

10.  Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401.

Authors:  Simani Gaseitsiwe; Davide Valentini; Shahnaz Mahdavifar; Marie Reilly; Anneka Ehrnst; Markus Maeurer
Journal:  Clin Vaccine Immunol       Date:  2009-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.